Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fellesskap, hjemmebasert utdanning, screeningtjenestestrategi for å øke tilgangen til kontroll av livmorhalskreft for HIV-positive kvinner i Nigeria

2. november 2026 oppdatert av: Lisa Flowers, Emory University

Strategi for fellesskap, hjemmebasert utdanning, screeningtjenester (CHESS) for å øke tilgangen til kontroll av livmorhalskreft for HIV-positive kvinner i Nigeria

The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims:

  • Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population.
  • Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity.
  • Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

Despite the increased risk of cervical cancer (CC) among women living with HIV (WLWH), access to CC screening in Nigeria remains limited. While advances in prevention programs and antiretroviral therapy have reduced other AIDS-associated malignancies, CC risk in WLWH persists. This study aims to leverage Nigeria's existing HIV treatment infrastructure to integrate home-based CC (HCC) screening for WLWH.

The approach involves adapting the MoMent (MOther MENTor) peer-based HIV support program to include HCC screening and evaluating its implementation and sustainability using the Consolidated Framework for Implementation Research (CFIR) and RE-AIM frameworks. The study has three key aims:

  • Adapting the MoMent program to promote home-based HPV screening and follow-up treatment through stakeholder deliberation.
  • Implementing and assessing the program's reach, effectiveness, adoption, and fidelity with a sample of 1,500 WLWH.
  • Conducting a post-implementation evaluation to identify barriers and enablers for program maintenance and scalability.

Stakeholder input, including perspectives from WLWH, peer counselors, clinical managers, and policymakers, will guide the program's design and execution. By integrating stakeholder insights and addressing systemic challenges, the study aims to advance CC control in Nigeria and provide a scalable model for implementing cancer control strategies for people living with HIV in low- and middle-income countries globally.

Studietype

Observasjonsmessig

Registrering (Antatt)

1500

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Abuja, Nigeria
        • APIN Health Initiatives
      • Ibadan, Nigeria
        • University of Ibadan
      • Lagos, Nigeria
        • Nigeria Institute of Medical Research (NIMR

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

25 år til 50 år (Voksen)

Tar imot friske frivillige

N/A

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Aim 1: The stakeholder deliberation conferences will include stakeholders from the following groups:

  • State and National Policymakers
  • Organizational-clinical managers
  • Mentor mothers
  • Women living with HIV (WLWH) Since this is a socio-behavioral component, pregnant individuals may partake. All individuals who take part in this portion of the study will be above 18 and capable of providing informed consent.

Aim 2: This study will only include WLWH aged 25-50. Pregnant individuals will not be included due to the potential for treatment of precancerous lesions. All individuals who partake in the study will be older than 18 and capable of providing informed consent.

Beskrivelse

Inclusion Criteria:

- Patients must be able to perform vaginal self-collection as well as give informed consent

Exclusion Criteria:

  • Male gender
  • Age <25 or >50
  • Unknown or negative HIV status
  • Pregnancy
  • Hysterectomy
  • Inability to give informed consent Inability/refusal to perform vaginal self-collection

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Women living with HIV

During the screening process:

  • Women testing negative for high-risk HPV (HrHPV) will complete participation one year after their test results, at which time they will be invited to retest.

  • Women living with HIV (WLWH) testing positive for HrHPV will have endpoints based on treatment outcomes:

    • Other HrHPV types (not 16/18/45):

      • Endpoint: One year post-VIA (visual inspection with acetic acid).
      • VIA-positive patients will receive thermal ablation treatment.
      • VIA-negative patients will have repeat VIA or standard screening after one year.
    • HrHPV types 16/18/45:

      • Endpoint: Two years post-treatment.
      • Follow-up includes repeat HPV self-collection, VIA, biopsies, and further treatment (thermal ablation or excision) if needed.

WLWH testing positive for HrHPV 16/18/45 via self-collection will be notified by a Mentor Mother, who, along with Nigerian clinical staff, will assist in scheduling VIA. Treatment follows the standard of care protocol.

The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care

Andre navn:
  • Øyeblikksprogram

A cervical cancer screening tool.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Program Reach
Tidsramme: Baseline, Month 6, Month 18

Reach evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or reoccurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load.

Baseline, Month 6, Month 18
Effectiveness of the Program
Tidsramme: Baseline, Month 6, Month 18

Effectiveness evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or recurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load.

Baseline, Month 6, Month 18
Adoption of the program
Tidsramme: Baseline, Month 6, Month 18

Adoption will be measured through the proportions of MMs who complete training and WLWH who return self-collected (SC) samples

Baseline, Month 6, Month 18
Fidelity of the program
Tidsramme: Baseline, Month 6, Month 18

Will be measured by peer leaders' monitoring of practices, as well as measuring system barriers and added MoMent program costs per completed home screening

Baseline, Month 6, Month 18

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Lisa Flowers, MD, MPH, Emory University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. desember 2024

Primær fullføring (Antatt)

1. august 2028

Studiet fullført (Antatt)

1. august 2028

Datoer for studieregistrering

Først innsendt

20. desember 2024

Først innsendt som oppfylte QC-kriteriene

20. desember 2024

Først lagt ut (Faktiske)

27. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Data shared:

De-identified sociodemographic data (e.g., race/ethnicity, age). Health behavior and health care utilization data from medical records. Cervical pathology results, HPV testing data, laboratory tests (e.g., CD4 and viral load), prescribed HIV medications, and adherence data.

Qualitative data from in-depth interviews and focus group discussions, coded and anonymized.

IPD-delingstidsramme

Start Date: After primary analyses have been completed and results are published (expected within 12 months of study completion).

End Date: Indefinitely, contingent on adherence to data-sharing agreements

Tilgangskriterier for IPD-deling

Researchers will submit a Data Analysis Request Form, detailing their proposed analysis, purpose, and data needed.

Data access will be granted following review and approval. Approved users will sign a Data Use and Confidentiality Agreement. Anonymized data will be shared securely via a designated data repository or encrypted file transfer.

Researchers must commit to using the data for specified purposes, implementing secure data storage, and destroying or returning the data after analyses are completed.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere